Adial Pharmaceuticals, Inc. engages in the development of therapeutics for the treatment or prevention of addiction and related disorders. The company is headquartered in Charlottesville, Virginia and currently employs 5 full-time employees. The company went IPO on 2018-07-27. The firm is focused on the development of therapies for the treatment and prevention of addiction and related disorders. The Company’s lead investigational new drug product, AD04, is a genetically targeted, serotonin-3 receptor antagonist, therapeutic agent for the treatment of Alcohol Use Disorder (AUD) in heavy drinking patients and was recently investigated in the Company’s ONWARD pivotal Phase III clinical trial for the potential treatment of AUD in subjects with certain target genotypes identified using the Company’s proprietary companion diagnostic genetic test. AD04 is also used for the treatment of other addictive disorders, such as Opioid Use Disorder, obesity, smoking, and other drug addictions. The Company’s wholly owned subsidiary is Purnovate, Inc.
Follow-Up Questions
Adial Pharmaceuticals Inc 'in CEO'su kimdir?
Mr. Cary Claiborne 2021 'den beri şirketle birlikte olan Adial Pharmaceuticals Inc 'in President 'ıdır.
ADIL hissesinin fiyat performansı nasıl?
ADIL 'in mevcut fiyatı $0.3631 'dir, son işlem günde 0.88% increased etti.
Adial Pharmaceuticals Inc için ana iş temaları veya sektörler nelerdir?
Adial Pharmaceuticals Inc Pharmaceuticals endüstrisine ait ve sektör Health Care 'dir
Wall Street analistlerine göre, 4 analist Adial Pharmaceuticals Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 2 güçlü al, 5 al, 2 tut, 0 sat ve 2 güçlü sat içermektedir
